← Back to Search

Johrei Therapy for Sleep Disturbances

N/A
Waitlist Available
Led By Sairam Parthasarathy, MD
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Medical and surgical patients with recent critical illness warranting ICU stay.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 2 weeks, 6 weeks
Awards & highlights

Study Summary

The purpose of this project is to compare the effectiveness of Johrei therapy (JT) and Cognitive-behavioral Therapy for Insomnia (CBT-I) in the treatment of sleep disturbances in survivors of critical illness. Subjects will be recruited following discharge from the Intensive Care Unit (ICU) and followed for 6 weeks. All subjects will undergo objective measurements of sleep quality and duration at baseline and at 6 weeks. Objective measurements will be made by portable (home-based) sleep studies and will wear a watch that measures sleep. Subjective measurements will be performed by sleep questionnaires: PSQI, Epworth sleepiness scale, sleep log, and Stanford Sleepiness Scale which will be performed at baseline, 2 and 6 weeks. A blood draw and urine collection will be done at both baseline and 6 weeks. The central purpose of this proposal is to perform a comparative-effectiveness study of a complementary and alternative approach (Johrei therapy) and CBT-I in the treatment of sleep disturbances in survivors of critical illness. The investigators hypothesize that, in survivors of critical illness, Johrei therapy is superior or comparable to CBT-I in improving sleep quality (Pittsburgh Sleep Quality Index [PSQI] and sleep efficiency [measured by polysomnography]). A secondary objective is to compare the effect of Johrei therapy and CBT-I on systemic markers of inflammation and urinary biomarkers of sleep and stress. The investigators hypothesize that, in survivors of critical illness, Johrei therapy is superior or comparable to CBT-I in reducing systemic markers of inflammation and urinary biomarkers of sleep and stress. A tertiary objective is to determine whether the presence of insomnia or other sleep characteristics is associated with hospital readmissions within 30-days.

Eligible Conditions
  • Sleep Disturbances

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 2 weeks, 6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 2 weeks, 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pittsburgh Sleep Quality Index (PSQI) (CBT-I, Johrei therapy)
Polysomnography (CBT-I, Johrei therapy)
Secondary outcome measures
Actigraphy (CBT-I, Johrei therapy)
Cytokines and Neurotransmitters (CBT-I, Johrei therapy)
Epworth Sleepiness Scale (ESS) (CBT-I, Johrei therapy)
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Johrei TherapyExperimental Treatment1 Intervention
3 sessions per week lasting 30 minutes. Daily report of bedtime and wake time. Baseline: Polysomnography Actigraphy Questionnaires Blood draw Urine collection 2 weeks: Questionnaires Actigraphy download Sleep log reconciliation 6 weeks: Polysomnography Actigraphy download sleep log reconciliation Questionnaires Blood draw Urine collection
Group II: Cognitive Behavioral Therapy for Insomnia (CBT-I)Active Control1 Intervention
1 session per week for a total of 6 weeks with the option of 2 additional sessions. Daily report of bedtime and wake time. Baseline: Polysomnography Actigraphy Questionnaires Blood draw Urine collection 2 weeks: Questionnaires Actigraphy download Sleep log reconciliation 6 weeks: Polysomnography Actigraphy download sleep log reconciliation Questionnaires Blood draw Urine collection

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor
516 Previous Clinical Trials
148,650 Total Patients Enrolled
The Johrei InstituteUNKNOWN
Sairam Parthasarathy, MDPrincipal InvestigatorUniversity of Arizona
11 Previous Clinical Trials
773 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~4 spots leftby May 2025